American Healthcare REIT, Inc. (AHR) Analyse boursière

Présentation de l'entreprise

American Healthcare REIT, Inc. operates as a Maryland-based self-managed Real Estate Investment Trust that owns and manages a diversified portfolio of clinical healthcare properties located across the United States, the United Kingdom, and the Isle of Man. The company focuses specifically on the Real Estate sector within the REIT - Healthcare Facilities industry, providing essential infrastructure for senior housing, skilled nursing facilities, and outpatient medical buildings. This entity employs 121 individuals to manage its extensive asset base, reflecting a mid-sized operational footprint relative to larger national property developers. With a market capitalization of $9.10B and annual revenue of $2.26B, the company demonstrates significant scale within the healthcare real estate landscape. These valuation and revenue figures indicate that the firm commands a substantial market presence, suggesting it is a major player capable of influencing local healthcare infrastructure markets while maintaining a distinct identity as a specialized REIT.

Santé financière

The company reported a Trailing Twelve Months (TTM) revenue of $2.26B, generating a net income of $69.81M and an EBITDA of $387.24M. The substantial gap between the $2.26B revenue and the $69.81M net income reveals a cost structure where operational expenses, including interest and management fees, consume approximately 97% of gross earnings before tax. Free cash flow stands at $341.35M, indicating that the company generates significant liquidity from its operations after capital expenditures, which provides a buffer for debt servicing or asset acquisitions. The gross margin is 18.3%, while the operating margin sits at 6.7% and the profit margin at 3.1%, illustrating that the business model relies on high volume to offset the heavy overhead costs inherent in managing large-scale real estate portfolios. Liquidity analysis shows the company holds $114.84M in cash against total debt of $1.69B, resulting in a debt-to-equity ratio of 50.20, which characterizes a highly leveraged balance sheet typical for REITs but requiring careful interest rate management. Short-term liquidity is constrained by a current ratio of 0.94, indicating that current assets are insufficient to cover current liabilities without relying on cash flow generation or asset sales. Finally, the Return on Equity is 2.5% and the Return on Assets is 2.1%, metrics that suggest management effectiveness is currently challenged by the high leverage levels and the capital-intensive nature of the healthcare real estate business.

Évaluation de la valorisation

The trailing twelve-month P/E ratio is 115.24, whereas the forward P/E is significantly lower at 49.56, implying that the market expects earnings to increase substantially in the future to justify the current high valuation multiple. The price-to-book ratio stands at 2.71, indicating that the market is pricing the company at a premium of roughly 171% over its net asset book value, reflecting confidence in the quality of its healthcare assets. Alternative valuation metrics such as the price-to-sales ratio of 4.03 and an EV/EBITDA of 27.66 further suggest that investors are willing to pay a high multiple for every dollar of revenue and earnings generated. The stock has traded between a 52-week low of $26.48 and a 52-week high of $54.67; without a specific current share price provided in the facts, the valuation context relies on these historical extremes to gauge recent price volatility and potential mean reversion dynamics. The beta value is 1.18, which indicates that the stock's price volatility is 18% higher than the broader market, suggesting it is more sensitive to market fluctuations than the average large-cap stock.

Growth & Income

Revenue growth for the trailing twelve months stands at 11.9%, while earnings growth is listed as N/A in the available data, preventing a direct comparison of earnings velocity against revenue expansion. In the absence of specific earnings growth figures to calculate a trajectory, the revenue expansion of 11.9% serves as the primary indicator of top-line business momentum. The company distributes a dividend with a yield of 2.1%, yet the payout ratio is 238.1%, which is mathematically unsustainable given that dividends paid exceed the reported net income. This high payout ratio suggests that a significant portion of the dividend is funded by cash flow or asset sales rather than current period earnings, a common practice for REITs but one that requires monitoring to ensure long-term sustainability. The overall growth and income profile is characterized by strong top-line revenue expansion tempered by a dividend structure that relies on cash flow mechanics rather than traditional earnings retention.